Last reviewed · How we verify
Consolidation, I HAM cycle
The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells.
The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells. Used for Acute myeloid leukemia (AML) consolidation therapy.
At a glance
| Generic name | Consolidation, I HAM cycle |
|---|---|
| Also known as | - Mitoxantrone, - Cytosine arabinoside [Ara-C] |
| Sponsor | dr hab. n. med. Agnieszka Wierzbowska |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a chemotherapy regimen used in consolidation therapy for acute myeloid leukemia (AML). Idarubicin and mitoxantrone are anthracycline topoisomerase II inhibitors that intercalate DNA and prevent strand separation, while high-dose cytarabine is a nucleoside analog that inhibits DNA synthesis. Together, these agents work synergistically to eliminate residual leukemic blasts after initial induction therapy.
Approved indications
- Acute myeloid leukemia (AML) consolidation therapy
Common side effects
- Myelosuppression
- Mucositis
- Infection
- Cardiotoxicity
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |